一品紅(300723.SZ):暢溪製藥是目前國內針對布地奈德/福莫特羅做改良創新進展最快的企業
格隆匯4月24日丨一品紅(300723.SZ)近日披露業績説明會、路演活動信息,交流環節中,就“公司在定期報吿中披露CXG87的研發情況,請問其產品具體情況,進展規劃以及未來的戰略與預期?”,公司回覆稱,CXG87是公司參股公司杭州暢溪製藥有限公司重點推進管線之一,已於今年申報臨牀並獲得批准,研究數據顯示,與已有產品相比,CXG87在可操作性、穩定性等諸多方面都顯示出一定的優勢,尤其在氣流依賴性方面有顯著改善,特別是對氣流受限的患者(如吸入氣流較小或肺活量較小患者)更為友好,有望進一步提升臨牀療效的穩定性。
暢溪製藥是目前國內針對布地奈德/福莫特羅做改良創新進展最快的企業。哮喘、COPD這類疾病有着巨大的臨牀需求,2021年國內公立醫院終端相關製劑全年銷售規模約為200億元。未來杭州暢溪將按照其戰略規劃推進項目。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.